Recent progress of napabucasin as privileged scaffold in the discovery of anticancer agents.
1/5 보강
Cancer is a major health issue worldwide, necessitating the development of novel treatments because treating this disease is challenging.
APA
Yang X, Ma G (2026). Recent progress of napabucasin as privileged scaffold in the discovery of anticancer agents.. European journal of medicinal chemistry, 305, 118559. https://doi.org/10.1016/j.ejmech.2026.118559
MLA
Yang X, et al.. "Recent progress of napabucasin as privileged scaffold in the discovery of anticancer agents.." European journal of medicinal chemistry, vol. 305, 2026, pp. 118559.
PMID
41494471
Abstract
Cancer is a major health issue worldwide, necessitating the development of novel treatments because treating this disease is challenging. Napabucasin, a furan-fused 1,4-naphthoquinone, exhibits significant anticancer activity through various molecular mechanisms and has become a privileged scaffold for developing antitumor therapeutics. In this review, we systematically evaluated recent progress in the use of napabucasin as a privileged scaffold for the discovery of antitumor drugs, focusing on structure-activity relationships (SARs), structural modification strategies, and the illustration of tumor inhibitory pathways from a mechanistic perspective. By conducting multidimensional assessments, we propose feasible directions for developing napabucasins with improved pharmacological properties for cancer treatment.
MeSH Terms
Naphthoquinones; Humans; Antineoplastic Agents; Structure-Activity Relationship; Drug Discovery; Benzofurans; Molecular Structure; Cell Proliferation; Neoplasms; Drug Screening Assays, Antitumor; Animals
같은 제1저자의 인용 많은 논문 (5)
- Clinical outcomes of endodontic microsurgery in complicated cases with large or through-and-through lesions: a retrospective longitudinal study.
- Neobavaisoflavone, a functional metabolite derived from valnemulin, ameliorates DSS-induced ulcerative colitis through activation of the AMPK signaling pathway.
- Spatiotemporally controlled ferritin-targeting PROTAC nanoplatform for visualized manipulation of endogenous "Iron pool" in pancreatic cancer therapy.
- CRISPR-Cas9 knockout screens to identify drug resistance genes in acute myeloid leukemia.
- Targeting the UFL1-AKT cascade suppresses triple-negative breast cancer progression.